Survey Report on Fibrocystic Breasts Diagnostics and Treatment Market Therapeutic In-depth Analysis 2018

Fibrocystic Breasts Diagnostics and Treatment Market

Fibrocystic breasts are a non-cancerous disease characterized by round lumps which move freely within the breast tissue and normally swell and shrink with the onset and end of the menstrual cycle. It is projected that 40% of all women in North America are suffering from fibrocystic breast disease. Fibrocystic breast changes are common in women of ages 20- 50. Drinking alcohol may increase the risk of having fibrocystic breast, especially in young women between 18 to 22 years of age. The symptoms are lumps, cyclic breast pain, tenderness, and nipple discharge.

Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, and Allergan plc.

The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.

Avail Sample Copy for This Report at: https://www.marketresearchfuture.com/sample_request/6448

The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users. On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs. On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes, and others.

Global Fibrocystic Breast Diagnostics and Treatment Market, by Type

Diagnosis
Mammogram
Breast biopsy
Treatment
Medications
Acetaminophen
Nonsteroidal anti-inflammatory drugs
Fine-needle aspiration
Surgical excision
Oral contraceptives


In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. More than half of women experience fibrocystic breast changes at some point in their lives. According to theĀ American Cancer Society’s evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.

The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.

Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.

The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Brows Detailed Report and Avail Discount Enquiry at: https://www.marketresearchfuture.com/reports/fibrocystic-breasts-diagnostics-treatment-market-6448

Fibrocystic breast changes are common in women of ages 20- 50. Drinking alcohol may increase the risk of having fibrocystic breast, especially in young women between 18 to 22 years of age. The symptoms are lumps, cyclic breast pain, tenderness, and nipple discharge.

Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively.

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

Leave a Reply

Your email address will not be published. Required fields are marked *